Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Operating Expenses (2021 - 2025)

PAVmed has reported Operating Expenses over the past 5 years, most recently at $6.9 million for Q4 2025.

  • Quarterly results put Operating Expenses at $6.9 million for Q4 2025, up 31.9% from a year ago — trailing twelve months through Dec 2025 was $21.9 million (down 37.32% YoY), and the annual figure for FY2025 was $21.9 million, down 53.93%.
  • Operating Expenses for Q4 2025 was $6.9 million at PAVmed, up from $4.8 million in the prior quarter.
  • Over the last five years, Operating Expenses for PAVM hit a ceiling of $24.7 million in Q4 2022 and a floor of $4.7 million in Q2 2025.
  • Median Operating Expenses over the past 5 years was $15.0 million (2024), compared with a mean of $14.4 million.
  • Biggest five-year swings in Operating Expenses: soared 145.44% in 2022 and later crashed 70.19% in 2024.
  • PAVmed's Operating Expenses stood at $20.0 million in 2021, then rose by 23.69% to $24.7 million in 2022, then decreased by 29.46% to $17.4 million in 2023, then crashed by 70.19% to $5.2 million in 2024, then surged by 31.9% to $6.9 million in 2025.
  • The last three reported values for Operating Expenses were $6.9 million (Q4 2025), $4.8 million (Q3 2025), and $4.7 million (Q2 2025) per Business Quant data.